170 related articles for article (PubMed ID: 9864601)
21. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
Fabbri G; Gorini M; Maggioni AP; Di Lenarda A;
G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354
[TBL] [Abstract][Full Text] [Related]
22. What can we learn from Europe?
Swedberg K
Heart; 2005 May; 91 Suppl 2(Suppl 2):ii21-3; discussion ii31, ii43-8. PubMed ID: 15831604
[TBL] [Abstract][Full Text] [Related]
23. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study.
Ferrari R;
Arch Intern Med; 2006 Mar; 166(6):659-66. PubMed ID: 16567606
[TBL] [Abstract][Full Text] [Related]
24. [Effect of the polymorphism of the angiotensin-converting enzyme gene on the drug treatment in patients with chronic heart failure].
Huang WY; Sun M; Zhou HY; Pei ZF; Yang TL
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Dec; 29(6):686-9. PubMed ID: 16114558
[TBL] [Abstract][Full Text] [Related]
25. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
[TBL] [Abstract][Full Text] [Related]
26. Applying standard therapies to new targets: the use of ACE inhibitors and B-blockers for heart failure in adults with congenital heart disease.
Vonder Muhll I; Liu P; Webb G
Int J Cardiol; 2004 Dec; 97 Suppl 1():25-33. PubMed ID: 15590076
[TBL] [Abstract][Full Text] [Related]
27. [Diastolic cardiac failure: therapeutic modalities].
Millaire A
Arch Mal Coeur Vaiss; 1998 Nov; 91(11):1365-9. PubMed ID: 9864605
[TBL] [Abstract][Full Text] [Related]
28. Heart failure: recent advances in prevention and treatment.
Fonarow GC
Rev Cardiovasc Med; 2000; 1(1):25-33, 54. PubMed ID: 12457149
[TBL] [Abstract][Full Text] [Related]
29. [Modern therapy of cardiac insufficiency].
Stojsić D; Jelkić N
Med Pregl; 1999; 52(3-5):113-24. PubMed ID: 10518395
[TBL] [Abstract][Full Text] [Related]
30. Pharmacologic therapies across the continuum of left ventricular dysfunction.
Abraham WT; Greenberg BH; Yancy CW
Am J Cardiol; 2008 Sep; 102(5A):21G-28G. PubMed ID: 18722188
[TBL] [Abstract][Full Text] [Related]
31. Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons.
Aronow WS
J Lab Clin Med; 2001 May; 137(5):316-23. PubMed ID: 11329528
[TBL] [Abstract][Full Text] [Related]
32. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
Saha SA; Molnar J; Arora RR
Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
[TBL] [Abstract][Full Text] [Related]
33. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy.
Jneid H; Moukarbel GV; Dawson B; Hajjar RJ; Francis GS
Am J Med; 2007 Dec; 120(12):1090.e1-8. PubMed ID: 18060931
[TBL] [Abstract][Full Text] [Related]
34. Strategies to attenuate pathological remodeling in heart failure.
Eapen Z; Rogers JG
Curr Opin Cardiol; 2009 May; 24(3):223-9. PubMed ID: 19318933
[TBL] [Abstract][Full Text] [Related]
35. The 2001 Canadian Cardiovascular Society consensus guideline update for the management and prevention of heart failure.
Liu P; Arnold M; Belenkie I; Howlett J; Huckell V; Ignazewski A; LeBlanc MH; McKelvie R; Niznick J; Parker JD; Rao V; Ross H; Roy D; Smith S; Sussex B; Teo K; Tsuyuki R; White M; Beanlands D; Bernstein V; Davies R; Issac D; Johnstone D; Lee H; Moe G; Newton G; Pflugfelder P; Roth S; Rouleau J; Yusuf S;
Can J Cardiol; 2001 Dec; 17 Suppl E():5E-25E. PubMed ID: 11773943
[No Abstract] [Full Text] [Related]
36. Heart failure due to left ventricular systolic dysfunction: treatment at discharge from hospital and at one year.
Houpe D; Peltier M; Cohen-Solal A; Béguin M; Lévy F; Slama M; Chapelain K; Tribouilloy C
Int J Cardiol; 2005 Sep; 103(3):286-92. PubMed ID: 16098391
[TBL] [Abstract][Full Text] [Related]
37. Changes in beta-adrenoceptors in heart failure due to myocardial infarction are attenuated by blockade of renin-angiotensin system.
Sethi R; Shao Q; Ren B; Saini HK; Takeda N; Dhalla NS
Mol Cell Biochem; 2004 Aug; 263(1-2):11-20. PubMed ID: 15524163
[TBL] [Abstract][Full Text] [Related]
38. The pharmacological treatment of heart failure: are we looking at the sunset of the neurohormonal hypothesis.
Porcu M
Ital Heart J; 2002 Jul; 3(7):437-8. PubMed ID: 12189976
[No Abstract] [Full Text] [Related]
39. [Left ventricular remodeling and ischemic heart diseases. Therapeutic possibilities].
Cohen-Solal A; Himbert D; Paillole C; Chikli F; Dahan M; Steg PG; Juliard JM; Gourgon R
Arch Mal Coeur Vaiss; 1991 Dec; 84 Spec No 4():63-7. PubMed ID: 1686544
[TBL] [Abstract][Full Text] [Related]
40. Prevention of remodeling of the heart after myocardial infarction.
Gorlin R
Mt Sinai J Med; 1995 Sep; 62(4):287-92. PubMed ID: 7565851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
